{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-238588","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2023-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.867682+00:00","generated_at":"2026-06-10T11:55:51.637397+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Forte Biosciences annual meeting: two directors elected, say-on-pay fails, equity plan approved","bullets":["Preliminary vote shows Eichenfield (16.4M for) and Wagner (16.8M for) elected; McIntyre and Hacke not elected.","Advisory vote on executive compensation failed: 9.9M for vs 11.8M against; abstentions 5.8M.","Amended 2021 Equity Incentive Plan approved: 16.8M for, 8.5M against, 2.1M abstentions.","Shareholder proposals to amend bylaws and remove preferred stock rights both defeated.","Ratification of auditor Mayer Hoffman McCann passed with 17.3M for; results subject to final certification."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-238588","json":"https://secwatch.observer/filing/0001193125-23-238588.json","markdown":"https://secwatch.observer/filing/0001193125-23-238588.md","text":"https://secwatch.observer/filing/0001193125-23-238588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/d538582d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T11:55:51.637397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"625538d0214f156e6845edb7bcb83912a521056d","claim":"Forte Biosciences, Inc. shareholders rejected Advisory Vote on Shareholder Proposal to Remove the Company’s Preferred Stock Rights Agreement at the 2023-09-19 meeting.","evidence_excerpt":"7. Advisory Vote on Shareholder Proposal to Remove the Company’s Preferred Stock Rights Agreement. The estimated preliminary votes for the advisory proposal to remove the preferred stock rights agreement are set forth below. Votes For Votes Against Abstentions 11,096,793 14,525,586 1,871,743","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm","confidence":0.85,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-09-19"}],"fact_type":"shareholder_vote"},{"claim_id":"6c47d61ae53964f243b5f847a1f6fef95c939981","claim":"Forte Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-09-19 meeting.","evidence_excerpt":"4. Ratification of Appointment of Independent Registered Public Accounting Firm. The estimated preliminary votes for the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 are set forth below. Votes For Votes Against Abstentions 17,303,222 3,776,436 6,502,444","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm","confidence":0.85,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-19"}],"fact_type":"shareholder_vote"},{"claim_id":"6f522c074616fe8dac8173b004acf81b34db316a","claim":"Forte Biosciences, Inc. shareholders voted on Frequency of Advisory Vote on Executive Compensation at the 2023-09-19 meeting.","evidence_excerpt":"3. Frequency of Advisory Vote on Executive Compensation. The estimated preliminary votes for the frequency of future advisory votes on executive compensation are set forth below. One Year Two Years Three Years Abstentions 13,958,000 35,449 9,869,970 3,630,703","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm","confidence":0.85,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Meeting","value":"2023-09-19"}],"fact_type":"shareholder_vote"},{"claim_id":"8461e05ae041a7864a8abc24a835ad9f4612d6ac","claim":"Forte Biosciences, Inc. shareholders rejected Advisory Vote on Executive Compensation at the 2023-09-19 meeting.","evidence_excerpt":"2. Advisory Vote on Executive Compensation. The estimated preliminary votes for the advisory vote on executive compensation are set forth below. Votes For Votes Against Abstentions 9,907,983 11,751,111 5,835,028","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm","confidence":0.85,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-09-19"}],"fact_type":"shareholder_vote"},{"claim_id":"b8810970e43da716de47140c9080525efea2792d","claim":"Forte Biosciences, Inc. shareholders rejected Shareholder Proposal to Amend the Amended and Restated Bylaws at the 2023-09-19 meeting.","evidence_excerpt":"6. Shareholder Proposal to Amend the Amended and Restated Bylaws. The estimated preliminary votes for the shareholder proposal to amend the Amended and Restated Bylaws are set forth below. Votes For Votes Against Abstentions 10,813,380 14,810,177 1,870,565","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm","confidence":0.85,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-09-19"}],"fact_type":"shareholder_vote"},{"claim_id":"ba9528fdd82355dc9d7f0a6f8df4244152edd30e","claim":"Forte Biosciences, Inc. shareholders voted on Election of Class III Directors at the 2023-09-19 meeting.","evidence_excerpt":"1. Election of Class III Directors. The estimated preliminary votes for each nominee are set forth below. The two nominees with the most votes in favor will be elected to the board after certification of the final results by the Inspector of Election: Nominee Votes For Votes Withheld Lawrence Eichenfield, M.D. 16,396,500 11,097,526 Paul A. Wagner, Ph.D. 16,831,738 10,662,288 Chris McIntyre 10,627,041 16,348,276 Michael G. Hacke 11,064,021 15,911,296","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm","confidence":0.85,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Meeting","value":"2023-09-19"}],"fact_type":"shareholder_vote"},{"claim_id":"e3172e326aab3eb25ae475ea99e5614270dde2a5","claim":"Forte Biosciences, Inc. shareholders approved Approval of the Amended and Restated 2021 Equity Incentive Plan at the 2023-09-19 meeting.","evidence_excerpt":"5. Approval of the Amended and Restated 2021 Equity Incentive Plan. The estimated preliminary votes for the adoption of the Amended and Restated 2021 Equity Incentive Plan are set forth below. Votes For Votes Against Abstentions 16,838,182 8,502,806 2,103,978","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523238588/0001193125-23-238588-index.htm","confidence":0.85,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-19"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}